Key facts
- This page summarizes Robert E. Waltermire's Form 3 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Aug 2021, 21:36.
Robert E. Waltermire - 02 Aug 2021 Form 3 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Reporting relationship
- Senior VP, Chief Pharma Dev.
- Issuer ticker
- MDGL
- Reported as of
- 02 Aug 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 04 Aug 2021, 21:36:58 UTC
- Next SEC filing
- 24 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian J. Lynch, As Attorney-in-fact for Reporting Person
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Waltermire filed Form 3 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 04 Aug 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.